Click for quick access:
Our Science
The NETest
NETest PPQ
PROSTest
Our Diagnostics and Your Patients
Liquid biopsy mRNA tests that characterize cancer with accuracy, sensitivity, and specificity
Delivering a cancer diagnosis to a patient is one of the most overwhelming tasks doctors are faced with. Initial patient reactions can be emotionally charged, marked by acute fear, doubt, sadness, or anxiety, all stemming from the uncertainty of the situation.
If your patient has been diagnosed with neuroendocrine cancer or prostate cancer, our molecular blood tests can remove some of the uncertainty from this diagnosis.
mRNA-based Molecular Cancer Test
Our diagnostic assesses a targeted gene profile of mRNA isolated from peripheral blood, enabling us to understand tumor disease activity*, recommend treatment, and then monitor recovery for NET, NEN, and prostate cancer patients in real-time. Quick and non-invasive, results from our liquid biopsy assays can be shared within 48 hours.
Expanding Usage Throughout the US
Our tests, which deliver higher levels of sensitivity, specificity, and accuracy than any other testing method available today, have been used over 10,000 times in medical centers throughout the United States. They help oncologists and patients manage and monitor treatment and quickly detect the recurrence of disease.
*Disease activity is defined as the calculated risk of highly active disease as measured by an algorithm based on gene expression data. Test results should be used in conjunction with standard clinical assessment.
Molecular Diagnostics
About Our Science
Current tests available from Wren Laboratories, which include our blood-based neuroendocrine cancer (NETest), our saliva-based COVID-19 test, and our soon-to-be offered prostate cancer (PROSTest) diagnostic are all reliant on the expression of mRNA found in liquid biopsies as a disease biomarker.
We use a real-time quantitative polymerase chain reaction (qPCR) process to amplify the circulating tumor-associated mRNAs before assessing them against a suite of proprietary algorithms we developed for each of the diseases we test.
Empirical Benefits
mRNA Diagnostic Performance
Be it blood or saliva, our molecular cancer tests provide actionable disease diagnostics in real-time.
Accuracy
The National Cancer Institute, peer-reviewed research, and our decades of experience demonstrate mRNA is unsurpassed for testing accuracy.
Sensitivity
The Wren Laboratories NETest has exhibited 98% sensitivity while the Wren PROSTest has demonstrated 95% sensitivity.
Specificity
The NETest has exhibited specificity levels in excess of 95% while preliminary results for our new PROSTest indicate 90% specificity.
carcinoid tumor, a type of NET.
PPQ is an accurate (>96%) predictor of patient response to PRRT
NETest Fast Facts
Four reasons to consider the NETest for your Neuroendocrine Tumor patients
Has been the subject of over 60 academic papers, peer-reviewed studies, and articles in medical journals.
Helps oncologists and patients manage and monitor treatment and quickly detect disease recurrence.
The NETest has been commercially available for almost 10 years and has been utilized over 10,000 times.
PROSTest
Introducing a less invasive, more accurate blood-based Prostate Cancer Diagnostic.
We have developed a multi-mRNA liquid biopsy biomarker assay that can help detect and define the molecular pathology of a patient’s prostate cancer with a simple blood test.
Our soon-to-be-released PROSTest is a blood-based, non-invasive diagnostic for prostate cancer that achieves over 90% confidence in accurately detecting PCa gene markers in blood samples. Like our NETest, this biomarker assay plays a crucial role in characterizing the molecular pathology of prostate cancer for treatment guidance and monitoring.
PC-3 human prostate cancer cells.
To be made aware when the PROSTest is available to the public, please click the link below to receive notification.